AnGes, Inc. (FRA:AJW)

Germany · Delayed Price · Currency is EUR

0.306

-0.010 (-3.16%)

At close: Dec 5, 2025

-3.77% (1Y)

Market Cap	140.93M
Revenue (ttm)	4.71M
Net Income (ttm)	-147.78M
Shares Out	n/a
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.318
Previous Close	0.316
Day's Range	0.306 - 0.318
52-Week Range	0.224 - 0.615
Beta	n/a
RSI	34.56
Earnings Date	Feb 10, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan. [Read more]

Industry Pharmaceutical Preparations

Founded 1999

Employees 55

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol AJW

Full Company Profile

Financial Performance

In 2024, AnGes's revenue was 643.00 million, an increase of 323.03% compared to the previous year's 152.00 million. Losses were -28.13 billion, 278.2% more than in 2023.

Financial numbers in JPY Financial Statements

News

There is no news available yet.